Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04813562
Recruitment Status : Recruiting
First Posted : March 24, 2021
Last Update Posted : March 24, 2021
Sponsor:
Collaborator:
Academy of Military Medical Sciences,Academy of Military Sciences,PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd
Information provided by (Responsible Party):
Jiangsu Province Centers for Disease Control and Prevention

Brief Summary:
This is a phase Ⅱ, randomized, placebo-controlled, double-blind study, to evaluate immunogenicity and safety of a recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) with an immunization procedure (0, 28, 56 days).

Condition or disease Intervention/treatment Phase
COVID-19 Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56 Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56 Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56 Phase 2

Detailed Description:

This is a phase Ⅱ, single-center, randomized, double-blind, placebo-controlled study, to evaluate the immunogenicity and safety of the recombinant COVID-19 vaccine (CHO cells) in the subjects from healthy adults and elderly adults aged 18 years and above (aged 18-60 and 60-85 years) . The phase Ⅱ clinical trials designed 4 research group, including an immunization procedures (0, 28, 56 days), two doses (20μg/0.5ml, 40μg/0.5ml) and two ages group (adults and elder): Each group including 120 participants. Vaccination or placebo group will be randomly assigned to receive in a 5:1 ratio, 480 in total.

Cellular immune blood samples were collected from the top 96 subjects (i.e., the top 24 in each study group, vaccine group: control group =5:1), and Elispot test and cytokine staining (ICS)/flow assay were performed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 480 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
Estimated Study Start Date : March 23, 2021
Estimated Primary Completion Date : July 30, 2021
Estimated Study Completion Date : June 30, 2022

Arm Intervention/treatment
Experimental: Middle-dose vaccine (18-59 years)
Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
18-59 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Experimental: High-dose vaccine (18-59 years)
Two doses of High-dose vaccine at the schedule of day 0, 28, 56
Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (18-59 years) at the schedule of day 0, 28, 56
18-59 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Experimental: Middle-dose vaccine (60-85 years)
Three doses of middle-dose experimental vaccine at the schedule of day 0, 28, 56
Biological: a middle-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
60-85 years,Three doses of middle-dose (20µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Experimental: High-dose vaccine (60-85 years)
Two doses of High-dose experimental vaccine at the schedule of day 0, 28, 56
Biological: a high-dose recombinant COVID-19 vaccine (CHO Cell) (60-85 years) at the schedule of day 0, 28, 56
60-85 years,Three doses of high-dose (40µg/0.5ml) recombinant COVID-19 vaccine (CHO Cell) at the schedule of day 0, 28, 56.

Placebo Comparator: Middle-dose placebo (18-59 years)
Three doses of middle-dose placebo at the schedule of day 0, 28, 56
Biological: a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56
18-59 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Placebo Comparator: High-dose placebo (18-59 years)
Two doses of High-dose placebo at the schedule of day 0, 28, 56
Biological: a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56
18-59 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Placebo Comparator: Middle-dose placebo (60-85 years)
Three doses of middle-dose placebo at the schedule of day 0, 28, 56
Biological: a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56
60-85 years,Three doses of middle-dose (0.5ml) placebo at the schedule of day 0, 28, 56.

Placebo Comparator: High-dose placebo (60-85 years)
Two doses of High-dose placebo at the schedule of day 0, 28, 56
Biological: a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56
60-85 years,Three doses of high-dose (0.5ml) placebo at the schedule of day 0, 28, 56.




Primary Outcome Measures :
  1. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays) [ Time Frame: 30 days after full-course vaccination in each study group ]
  2. The incidence of adverse reaction (AR) [ Time Frame: 0 to 7 days after vaccination in each study group ]

Secondary Outcome Measures :
  1. The incidence of adverse events (AE) [ Time Frame: 0 to 30 days after vaccination in each study group ]
  2. The incidence of severe adverse events (SAE) [ Time Frame: 12 months after prime and boost vaccination ]
  3. The Geometric mean titer (GMT) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays) [ Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group ]
  4. The Geometric mean fold increase (GMI) of anti-SARS-CoV-2 specific neutralizing antibody (euvirus and pseudovirus neutralization assays) [ Time Frame: 14 days, 30 days, 6 months and 12 months after full-course vaccination in each study group ]
  5. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (eucivirus neutralization assays) [ Time Frame: 14 days, 6 months and 12 months after full-course vaccination in each study group ]
  6. The positive conversion rate of anti-SARS-CoV-2 specific neutralizing antibody (pseudovirus neutralization assays) [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
  7. The positive conversion rate of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
  8. The GMT of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
  9. The GMI of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]

Other Outcome Measures:
  1. The geometric mean titer (GMT) ratio of the SARS-CoV-2 neutralizing antibody and the S-RBD protein specific antibody in each study groups [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
  2. Subtypes of IgG antibodies against the S-RBD protein of SARS-CoV-2 after immunization in each study group [ Time Frame: 14 days, 30days, 6 months and 12 months after full-course vaccination in each study group ]
  3. The proportion of IFN-γ secreted by T cells at Day 14 using ELISpot detection method [ Time Frame: Day 14 after full-course vaccination in each study group ]
  4. The Intracellular cytokine staining (ICS)/flow cytometry was used to detect the Th1/Th2 immune response after immunization (CD3+/CD4+/CD8+ T cells, and cytokines TNFα/IFNγ/IL2/IL4). [ Time Frame: Day 14 after full-course vaccination in each study group ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects of ≥ 18 years old.
  • The subject can understand and voluntarily sign the informed consent.
  • Axillary temperature ≤37.0℃.
  • General good health as established by medical history and physical examination

Exclusion Criteria:

  • Have a history of close contact with a confirmed case of SARS-CoV-2, an asymptomatic infection in the previous 14 days, or a travel history/residential history in a community where a case has been reported.
  • Have a history of contact with a person infected with SARS-CoV-2(a person with a positive nucleic acid test) in the previous 14 days.
  • Patients with fever or respiratory symptoms who have been to middle or high-risk areas in the past 14 days or have exit history, or come from communities with case reports.
  • In the past 14 days, there have been 2 or more cases of fever and/or respiratory symptoms in small areas such as homes, offices, school classes, etc.
  • Have a history of SARS.
  • Have a history of SARS-CoV-2 infection or history of Coronavirus Vaccination (including Emergency Vaccine and Experimental Vaccine).
  • Positive in SARS-CoV-2 IgG or IgM antibody screening.
  • Have a history of HIV infection;
  • Women who are breastfeeding, pregnant, or planning to become pregnant during 6 months after full-course vaccination (based on the subject's self-report and blood pregnancy test results for women of childbearing age).
  • Have a history of asthma, a history of vaccine or vaccine component allergy, have serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema.
  • Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
  • Subjects with autoimmune diseases or immunodeficiency/immunosuppression.
  • Subjects with severe chronic diseases, severe cardiovascular diseases, hypertension(sbp≥160mmHg and/or dbp≥100mmHg) and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.
  • Subjects with severe neurological disease (epilepsy, convulsions or convulsions) or mental illness.
  • Subjects with thyroid disease or history of thyroidectomy, no spleen, functional asthenia, and any spleen or splenectomy caused by any condition.
  • Abnormal blood coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulopathy, abnormal platelet) or obvious bruise or coagulation disorder.
  • Have received immunosuppressant therapy, cytotoxic therapy, and inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-complicated dermatitis).
  • Received blood products within 3 months before receiving trial vaccine.
  • Received other study drugs within 30 days before receiving the trail vaccine.
  • Received a live attenuated vaccine within 14 days before receiving the experimental vaccine.
  • Received a subunit or inactivated vaccine within 7 days before receiving the experimental vaccine.
  • Various acute or chronic diseases occurred in the past 7 days.
  • Have a long history of alcohol or drug abuse.
  • Had urticaria one year before receiving the experimental vaccine;
  • congenital or acquired angioedema/neuroedema;
  • According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial, or Or influence the subject to sign the informed consent.

Exclusion criteria of subsequent dose:

  • Patients with severe allergic reactions after the previous dose of vaccination;
  • Patients with serious adverse reactions causally related to the previous dose of vaccination.
  • For those newly discovered or newly discovered after the first vaccination that does not meet the first-dose selection criteria or meets the first-dose exclusion criteria, the investigator will determine whether to continue participating in the study.
  • Other exclusion reasons suggested by the researchers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04813562


Contacts
Layout table for location contacts
Contact: Fanyue Meng, Doctor 18915999245 mfy19780712@163.com

Locations
Layout table for location information
China, Jiangsu
Jiangsu Provincial Center for Diseases Control and Prevention Recruiting
Nanjing, Jiangsu, China
Contact: Mingwei Wei    15950529760    wnmcwmw@163.com   
Sponsors and Collaborators
Jiangsu Province Centers for Disease Control and Prevention
Academy of Military Medical Sciences,Academy of Military Sciences,PLA ZHONGYIANKE Biotech Co, Ltd. LIAONINGMAOKANGYUAN Biotech Co, Ltd
Investigators
Layout table for investigator information
Principal Investigator: Fengcai Zhu, Doctor Jiangsu Provincial Center for Disease Control and Prevention
Layout table for additonal information
Responsible Party: Jiangsu Province Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier: NCT04813562    
Other Study ID Numbers: JSVCT097
First Posted: March 24, 2021    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jiangsu Province Centers for Disease Control and Prevention:
Immunogenicity
Safety
COVID-19 vaccine
Recombinant vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Vaccines
Immunologic Factors
Physiological Effects of Drugs